← Back
Data updated: Mar 29, 2026
ASPIRO
Infectious DiseaseDermatologyCardiovascular
Generics
ASPIRO is a generic drug manufacturer focused on Infectious Disease, Dermatology, Cardiovascular.
2020
Since
26
Drugs
-
Trials
406
Approved (2yr)
Key Drugs
No active drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 40%
4 drugs
Dermatology 20%
2 drugs
Cardiovascular 20%
2 drugs
Neurology 10%
1 drugs
Gastroenterology 10%
1 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Pfizer big-pharma
Infectious Disease, Dermatology, Gastroenterology
APOTHECON specialty
Infectious Disease, Dermatology, Cardiovascular, Gastroenterology
Baxter specialty
Infectious Disease, Cardiovascular, Dermatology
LEDERLE big-pharma
Infectious Disease, Cardiovascular, Neurology, Dermatology
PAI HOLDINGS PHARM big-pharma
Dermatology, Infectious Disease, Neurology, Cardiovascular
Active (17)
SUGAMMADEX SODIUM POSACONAZOLE SELENIOUS ACID DAPTOMYCIN PHENYLEPHRINE HYDROCHLORIDE VORICONAZOLE PANTOPRAZOLE SODIUM NOREPINEPHRINE BITARTRATE PROPOFOL KETOROLAC TROMETHAMINE BUMETANIDE ZINC SULFATE VANCOMYCIN HYDROCHLORIDE MAGNESIUM SULFATE VERAPAMIL HYDROCHLORIDE DOXYCYCLINE HYCLATE SUCCINYLCHOLINE CHLORIDE
Discontinued (9)
Company Info
- First Approval
- 2020-05-04
- Latest
- 2025-11-13
- Applications
- 28